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Much of our knowledge about cartilage and bone has 
come from descriptive anatomy, endocrinology, and cellu- 
lar studies of bone turnover. Recent approaches have led 
to the identification of local factors that regulate skeletal 
morphogenesis. Molecular and biochemical studies of 
bone and cartilage cells in vitro, gene inactivation in mice, 
and the identification of genes responsible for mouse and 
human skeletal abnormalities have documented the im- 
portance of specific growth and differentiation factors, ex- 
tracellular matrix proteins, signaling mediators, and tran- 
scription factors in bone and cartilage development. The 
successful convergence of mouse and human genetics in 
skeletal biology is illustrated in this issue of Cell with two 
papers that show that mutations in collagen type Xl cause 
chondrodysplasia both in cho/cho mice as well as in pa- 
tients with Stickler syndrome (Li et al., 1995; Vikkula et 
al., 1995). 
In general, recent results emphasize the need to view 
skeletal development at various integrated levels of orga- 
nization and illustrate how single gene products affect de- 
velopment at these different levels. Pattern information 
determines not only the body plan of the early skeleton 
but also the shape of each individual skeletal element. In 
addition, the sequence of events during bone growth and 
development must be temporally and spatially controlled 
to ensure correct proportions of bony elements. Positional 
information must also regulate the establishment of bone 
internal structure throughout growth, while local homeo- 
static mechanisms must maintain bone integrity through- 
out adult life. Lastly, a complex extracellular matrix must 
generate skeletal tissues with specific biomechanical 
properties. 
Ultimately, the morphogenesis of the skeleton derives 
from the regulated differentiation, function, and interac- 
tions of its component cell types. Three major cell types 
contribute to the skeleton: chondrocytes, which form carti- 
lage; osteoblasts, which deposit bone matrix; and osteo- 
clasts, which resorb bone. Chondrocytes and osteoblasts 
are of mesenchymal origin, whereas osteoclasts derive 
from the hematopoietic system. Once embedded in bone 
matrix, osteoblasts mature into terminally differentiated 
osteocytes. The activity and differentiation of osteoblasts 
and osteoclasts are closely coordinated during develop- 
ment as bone is formed and during growth and adult life 
as bone undergoes continuous remodeling. More specifi- 
cally, the formation of internal bone structures and bone 
remodeling result from coupling bone resorption by acti- 
vated osteoclasts with subsequent deposition of new ma- 
trix by osteoblasts (Figure 1). Bone remodeling also links 
bone turnover to the endocrine homeostasis of calcium 
and phosphorus, since the mineralized bone matrix serves 
as the major repository for these ions in the body. 
Descriptive embryology and anatomy distinguish two 
types of bone development: intramembranous and endo- 
chondral. Intramembranous ossification occurs when 
mesenchymal precursor cells differentiate directly into 
bone-forming osteoblasts, a process employed in generat- 
ing the flat bones of the skull as well as in adding new 
bone to the outer surfaces of long bones. In contrast, endo- 
chondral bone formation entails the conversion of an initial 
cartilage template into bone and is responsible for generat- 
ing most bones of the skeleton. Cartilage templates origi- 
nally form during embryogenesis when mesenchymal 
cells condense and then differentiate into chondrocytes. 
These cells subsequently undergo a program of hypertro- 
phy, calcification, and cell death. Concomitant neovascu- 
larization occurs, and osteoclasts and osteoblasts are re- 
cruited to replace the cartilage scaffold gradually with 
bone matrix and to excavate the bone marrow cavity. Lon- 
gitudinal bone growth takes place through a similar pattern 
of endochondral ossification in the growth plates located 
at the epiphyses (ends) of long bones. In these epiphyseal 
plates, the calcified, hypertrophic cartilage provides a 
scaffold for the formation of new trabecular bone. Ulti- 
mately, all remaining cartilage is replaced by bone except 
at the articular surfaces of the joints (Figure 2). 
Skeletal Patterning 
Classical embryology has shown that three distinct embry- 
onic lineages contribute to the early skeleton. The neural 
crest gives rise to the branchial arch derivatives of the 
craniofacial skeleton, the sclerotome generates most of 
the axial skeleton, and the lateral plate mesoderm forms 
the appendicular skeleton. Transplantation studies have 
indicated that information regarding the number and ana- 
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Figure 1. Bone Remodeling 
During a remodeling cycle, activated multinucleated osteoclasts de- 
rived from bone marrow monocytes resorb a discrete area of mineral- 
ized bone matrix. Subsequently, capillary endothelial cells provide the 
microvasculature, and cuboidal osteoblasts and fibroblastic osteopro- 
genitor cells, which can locally proliferate and differentiate into osteo- 
blasts, migrate into the resorption lacuna. The osteoblasts deposit 
new bone matrix, which is initially unmineralized and called osteoid, 
and in this way refill the resorption lacuna. Once embedded in osteoid, 
the osteoblasts mature into terminally differentiated osteocytes. 
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Figure 2. Long Bone Growth through Endochondral Ossification 
Longitudinal bone growth occurs at the epiphyseal growth plate in 
which chondrecytes proliferate and mature, and the calcified matrix 
of the hyperytrophic cartilage provides ascaffold for new trabecular 
bone formation. Above the growth plate, the secondary ossification 
center has already replaced the epiphyseal cartilage with bone and 
bone marrow. 
tomic "identity" of derived skeletal elements already re- 
sides in these lineages by the time of their appearance 
and long before overt skeletogenesis. 
The family of transcription factors encoded by homeo- 
box genes play a central role in this aspect of skeletal 
pattern formation (reviewed by Morgan and Tabin, 1993; 
Krumlauf, 1994). Specific homeobox genes are expressed 
in distinct patterns at the time when the embryonic lin- 
eages initially form. Furthermore, targeted inactivation or 
ectopic expression of these genes in the mouse results 
in the deletion or addition of skeletal elements or in the 
transformation of skeletal elements into shapes resem- 
bling other elements. For example, the hoxa-2 gene is 
expressed in fourth rhombomere neuroepithelium before 
the migration of neural crest cells and their subsequent 
differentiation into the skeletal elements of the second 
branchial arch. Its localized expression combined with the 
results from transplantation experiments Suggests that 
this gene is required for the determination of second 
branchial arch identity. Accordingly, inactivation of the 
hoxa-2 gene results in the deletion of the craniofacial ele- 
ments derived from the second branchial arch and their 
replacement by elements resembling those derived from 
the first branchial arch (Gendron-Maguire t al., 1993; Rijli 
et al., 1993). Thus, in the absence of the hoxa-2 gene 
product, the skeletogenic neural crest of the second arch 
defaults to a first arch identity. The same principles can 
be demonstrated for the axial and appendicular skeleton 
using the hoxd-13 homeobox gene as an example, hoxd- 
13 is expressed in the presomitic mesoderm of the poste- 
rior region of the embryo before sclerotome formation and 
appearance of the mesodermal skeletal lineages, as well 
as in the posterior distal region of the limb bud mesen- 
chyme. Inactivation of the hoxd-13 gene results in a trans- 
formation of the fourth sacral vertebrae into a bone re- 
sembling the third and in an assortment of deletions 
and additions of distal limb skeletal elements (Doll~ 
et al., 1993). 
The well-studied system of limb development has re- 
vealed the additional importance of inductive interactions 
in regulating skeletal patterning. Signals essential for limb 
patterning emanate from the zone of polarizing activity 
(ZPA), which is located in the posterior limb mesoderm 
underlying the apical ectodermal ridge (AER) of a devel- 
oping limb bud. Transplantation of the ZPA underneath 
the AER on the anterior margin of another limb bud results 
in a mirror-image duplication of skeletal elements, a phe- 
nomenon that also occurs when retinoic acid is applied 
at the same anterior site. The secreted factor Sonic hedge- 
hog (Shh) has been identified as a key inductive signal 
that mediates the activity of the ZPA (Riddle et al., 1993). 
Shh induces fibroblast growth factor 4 (FGF-4) in the AER, 
which in turn also regulates Shh expression and serves 
as an ectodermal competence factor for Shh respon- 
siveness in the underlying mesoderm (Laufer et al., 1994). 
These inductive interactions may regulate limb skeletal 
patterning by establishing the expression patterns of ho- 
meobox genes in the limb bud mesenchyme. For example, 
Shh induces the local expression of hoxd-13, which, as 
mentioned above, is required for normal limb patterning. 
Shh also induces the local expression of bone morphoge- 
netic protein 2 (BMP2), a transforming growth factor 13 
(-rGFl~)-related factor with cartilage-inducing activity. Simi- 
lar inductive interactions are likely to play an important 
role in skeletal patterning in other areas of the developing 
embryo. 
Local Control of Bone Shape 
The individual shapes of skeletal elements are largely 
determined uring embryogenesis when their respective 
cartilage templates form from localized mesenchymal con- 
densations. The importance of paracrine factors in regulat- 
ing the process of mesenchymal condensation has been 
emphasized by the recent characterizations of the mouse 
mutations hort ear (se) and brachypodism (bp) (reviewed 
by Kingsley, 1994). In these mutant mice, various skeletal 
elements thoughout he body have altered shapes and 
sizes. For example, the se phenotype includes an altered 
shape of the sternum and the external ear cartilage, whereas 
the bp mutation leads to a reduction in size of appendicular 
long bones. These adult abnormalities can be attributed 
to defects in size and shape already apparent in the mes- 
enchymal condensations of the affected skeletal elements. 
The se and bp mutations result from inactivation of the 
genes for BMP5 and GDF-5 (for growth and differentiation 
factor 5), two members of the TGF~ superfamily, respec- 
tively (Kingsley et al., 1992; Storm et al., 1994). The devel- 
opmental expression pattern of these two factors is consis- 
tent with their potential role in the local control of patterns 
of mesenchymal condensations. For example, BMP5 is ex- 
pressed in condensing mesenchyme, which gives rise to 
external ear cartilage, whereas GDF-5 is expressed in 
mesenchyme surrounding limb condensations. Further- 
more, the ability of BMP5 and other BMPs to induce carti- 
lage and bone formation when injected into nonskeletal 
sites in vivo further supports a role for these factors in the 
local induction of cartilage. These factors may also be 
involved in fracture repair, as suggested by the increased 
expression of BMP4 at fracture sites (Nakase et al., 1994) 
and the impaired fracture healing in se mice. 
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The current data on the regulation of skeletogenesis 
suggest a two-step model for the specification of the pat- 
tern and shape of the embryonic skeleton. First, the pat- 
terned expression of homeobox genes confers information 
to cells of the early mesenchymal lineages that specifies 
the overall pattern of the skeleton and the archetypal 
shape and identity of the individual elements. Second, the 
shape of a skeletal element is further defined through the 
local regulation of mesenchymal condensation by se- 
creted autocrine/paracrine factors. Phylogenetic evolution 
of the skeleton may result from modifications in early cell- 
intrinsic patterning and in local control of mesenchymal 
condensation by these differentiation factors. 
Bone Shape during Growth 
Bone growth is regulated by various systemic factors. 
Skeletal growth ultimately ceases when the growth plate 
is entirely replaced with bone, a process that requires es- 
trogen in both males and females (Federman, 1994; Smith 
et al., 1994). The rate of skeletal growth until epiphyseal 
closure is regulated by growth hormone, which is released 
by the pituitary gland and acts predominantly through the 
local and systemic expression of insulin-like growth factor 
1 (IGF-1). Mice that lack IGF-1 as a result of gene inactiva- 
tion (Baker et al., 1993) and humans with reduced growth 
hormone levels resulting in hypopituitary dwarfism have 
a reduced size of the skeleton, but with only small alter- 
ations of the proportions between or within bones. 
During growth, maintenance of the shapes of indK, idual 
bones and the relative proportions of the skeleton are likely 
to result from a complex process involving multiple local 
mediators, as suggested by the wide spectrum of clinical 
abnormalities related to disproportionate bone growth. In 
the skull, the intramembranous bones grow by peripheral 
addition of new bone at osteogenic fronts, which generate 
the suture lines. Osteoblastic differentiation within the su- 
tures and consequent bone deposition are intimately coor- 
dinated with the growth of the skull and the timing of suture 
closure. Deregulated coordination results in premature su- 
ture closure, leading to various skull abnormalities collec- 
tively known as craniosynostoses. In bones that develop 
based on cartilage templates, endochondral ossification 
must be coordinated with the simultaneous growth of the 
epiphyses, longitudinal growth at the epiphyseal growth 
plate, and the radial growth of the periosteum. Achondro- 
plasia, the most common cause of human dwarfism, re- 
sults from incomplete coordination of these processes and 
is characterized by short, wide bones and overgrowth of 
the periosteum relative to the epiphyses. 
Recently, cell signaling by FGFs has been implicated 
in coordinating proportional bone growth. At least nine 
members of the FGF family interact with varying specifici- 
ties and affinities to four transmembrane tyrosine kinase 
FGF receptors, FGFR1 through FGFR4 (reviewed by Givol 
and Yayon, 1992). FGF receptor signaling regulates vari- 
ous cellular processes, most notably the proliferation and 
differentiation of cells of mesenchymal and neurectoder- 
mal origin. Recently, several dominantly inherited human 
skeletal disorders have been correlated with mutations in 
FGF receptors. Mutations in the transmembrane region 
of FGFR3 in patients with achondroplasia suggests that 
impaired ligand-induced receptor dimerization and signal- 
ing may be the cause of this disease (Rousseau et al., 
1994; Shiang et al., 1994). The expression of FGFR3 in 
resting chondrocytes and not in the periosteum (Peters 
et al., 1993) may explain why achondroplasia results in 
abnormalities in only those bones that develop based on 
cartilage templates and not in the intramembranous bones 
of the skull. The craniosynostosis een in Crouzon syn- 
drome has been correlated with mutations in the extracel- 
lular domain of FGFR2, which may affect ligand binding 
(Reardon et al., 1994). Finally, patients with Pfeiffer syn- 
drome and Jackson-Weiss syndrome, which have cranio- 
synostoses as well as limb defects, have similar mutations 
in FGFR1 and FGFR2, respectively (Jabs et al., 1994; 
Muenke et al., 1994). It is unclear how different point muta- 
tions in FGFR2 give rise to different skeletal defects in 
Crouzon syndrome and Jackson-Weiss syndrome. The 
identification of these mutations in these inherited skeletal 
disorders implies a local role of FGF-mediated signaling 
in skeletal development and suggests transgenic ap- 
proaches to the characterization ofthe role of these factors 
in skeletal development. 
The restricted expression patterns of the FGFRs and 
their ligands and in vitro data on the effects of FGFs sug- 
gest that specific FGFs might regulate intrinsic growth 
rates of distinct zones of the epiphysis and that FGF- 
mediated autocrine and paracrine interactions within and 
between these zones control their relative growth. An inter- 
nal network of local homeostatic interactions via FGFs 
might then be integrated with effects of systemic factors 
to control overall skeletal growth and proportions. 
Further evidence for such an integration of signals and 
communication between different zones of the epiphyseal 
plate comes from studies on parathyroid hormone-related 
protein (PTHrP). While PTHrP is expressed in various loca- 
tions throughout the epiphysis, its receptor expression in 
growth plate cartilage is localized mainly to the transitional 
zone between proliferating and hypertrophic hondro- 
cytes, suggesting that cells in this zone coordinate the 
rate of chondrocyte maturation. In mice with an inactivated 
PTHrP gene, the reduced proliferation and premature dif- 
ferentiation of chondrocytes in the epiphyseal plate lead 
to a greatly increased rate of endochondral ossification, 
resulting in a skeleton that is almost completely ossified 
by the time of birth (Amizuka et al., 1994; Karaplis et al., 
1994). 
Possibly related to growth factor signaling in skeletal 
growth control is the recent finding that diastrophic dyspla- 
sia can be ascribed to a defect in the gene for a putative 
sulfate transporter (H&stbacka et al., 1994). In this dis- 
ease, the undersulfation of proteoglycans may be respon- 
sible for the mechanical defects in cartilage and bone ma- 
trix that result in a severely malformed skeleton, progressive 
joint disease, and dwarfism. The deformities in diastrophic 
dysplasia and the FGF-related diseases described above 
share some similarities. For example, in diastrophic dys- 
plasia, the deformities in the short bones are similar to 
those seen in achondroplasia, the broad great toes are 
similar to Jackson-Weiss and Pfeiffer syndromes, and the 
broad thumbs are reminiscent of Pfeiffer syndrome. A 
mechanistic basis for the relationship between these two 
types of diseases is also suggested by the requirement 
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of heparan sulfates for the high affinity interactions of FGF 
with its receptor (Yayon et al., 1991; Givol and Yayon, 
1992). Whether the defect in sulfation in diastrophic dys- 
plasia decreases the availability of heparan sulfates and 
impairs FGF signaling during skeletal development re- 
mains to be tested. 
The importance of transcription factors in the regulation 
of bone growth is illustrated by the mutation in the msx2 
homeobox gene in patients with Boston-type craniosy- 
nostosis (Jabs et al., 1993). Consistent with its involve- 
ment in suture function and closure, msx2 mRNA is local- 
ized at the sutures and various other sites during 
craniofacial development of the mouse. Inactivation of the 
closely related msxl further suggests that this class of 
homeobox genes plays a role in normal growth of intra- 
membranous bones at osteogenic fronts (Satokata and 
Maas, 1994). The cleft palate in these mice is due to failu re 
of the palatal shelves to grow toward each other and fuse 
and is consistent with the expression of msxl in the os- 
teogenic fronts of the palatal shelves. Remarkably, the 
expression of both msxl and msx2 has been shown, at 
least in developing teeth, to be controlled by BMP4, a 
TGFI~ related factor with cartilage- and bone-inducing ac- 
tivity (Vainio et al., 1993). Lastly, mutations in SOX9, which 
encodes a putative transciption factor related to SRY, 
have been shown to cause sex reversal with associated 
campomelic dysplasia, a congenital skeletal malformation 
syndrome with the prominent feature of bowed long bones 
(Foster et al., 1994; Wagner et al., 1994). How this gene 
product is involved in bone development is unknown. 
Bone Structure, Modeling, and Remodeling 
The coordinated activities of osteoclasts and osteoblasts 
in bone resorption and deposition form the internal struc- 
ture of a bone. In long bones, a tube of dense cortical 
bone encases the bone marrow space and is capped by 
the two epiphyseal growth plates. The bone marrow cavity 
contains a large number of bone spicules (trabeculae) ar- 
ranged with increasing density toward the epiphyseal 
plates (Figure 2). The importance of bone resorption in 
bone modeling is illustrated by the structural defects in 
osteopetrosis, a disease associated with impaired osteo- 
clastic function. While the external shapes are normal, 
osteopetrotic bones are characterized by a homogeneous 
dense trabeculation in the bone marrow space and a less 
compact consistency of the cortical bone. In several 
mouse models, the inactivation of specific genes results 
in impaired osteoclastic differentiation and consequent os- 
teopetrosis. In osteopetrotic op/op mice, osteoclast differ- 
entiation is blocked at an early stage as a result of defective 
production of colony-stimulating factor 1 (CSF-1) (Wiktor- 
Jedrzejczak et al., 1990; Yoshida et al., 1990). The inability 
of bone marrow transplantation to cure this form of os- 
teopetrosis uggests that CSF-1 is normally provided by 
cells external to the hematopoietic system. In contrast, 
several other types of osteopetrosis in mice can be res- 
cued by bone marrow transplantation. For example, rail 
mi mice develop osteopetrosis as a result of a mutation 
in a putative transcription factor that contains a basic- 
helix-loop-helix (bHLH) domain and a leucine zipper do- 
main (Hodgkinson et al., 1993). In addition, inactivation 
of the c-src gene results in a rescuable osteopetrosis in 
which the multinucleated osteoclasts are present but lack 
bone resorption activity (Lowe et al., 1993; Soriano et al., 
1991). Finally, inactivation of the c-fos gene also results 
in osteopetrosis, but in this case the phenotype is due to 
a complete absence of differentiated osteoclasts (Grigori- 
adis et al., 1994). The expression of c-fos in differentiating 
osteoclasts and the rescue of the phenotype following 
transplantation of normal bone marrow suggest that this 
transcription factor is required for early osteoclast differen- 
tiation. Taken together, these mouse mutations not only 
emphasize the importance of osteoclastic activity in both 
the resorption of trabecular bone and the establishment 
of the definitive cortex, but also implicate several factors 
in osteoclast differentiation and activity. 
Mechanical tension can also alter local bone architec- 
ture by influencing bone remodeling. The requirement for 
mechanical tension in the formation of bony tubercles at 
sites of tendon insertions is elegantly demonstrated in 
mice in which both the myf-5 and myoD genes are inacti- 
vated (Rudnicki et al., 1993). These mice lack bony tuber- 
cles presumably as a result of impaired muscle develop- 
ment and therefore reduced mechanical tension at tendon 
insertion sites. While prostaglandins have been impli- 
cated, how tension is sensed by resident bone cells and 
how such signals contribute to the cellular and molecular 
control of bone remodeling are major unresolved issues 
in skeletal biology. 
Bone remodeling itself is a poorly understood process. 
While much is known about the kinetics of bone turnover 
at the cellular level, little is understood about the local 
regulation of bone remodeling at the molecular level (re- 
viewed by Canalis et al., 1991). Presumably, specific fac- 
tors regulate each step of a remodeling cycle, the coor- 
dination of remodeling with the local differentiation of 
osteoclasts and osteoblasts from their respective precur- 
sor cell populations, and the integration of bone remodel- 
ing with the endocrine control of bone turnover. Under- 
standing these vario'us levels of control is important 
because deregulated bone remodeling lies at the basis of 
many metabolic bone diseases. For example, osteoporo- 
sis is characterized by reduced bone mass and is thought 
to result from an imbalance between bone formation and 
resorption. While the association of this disease with endo- 
crinological imbalances such as reduced estrogen and 
increased corticosteroids has long been apparent, how 
these systemic factors influence the local regulation of 
bone remodeling is still not known. A recent example of 
this dichotomy comes from the association of reduced 
bone density with common alleles of the gene encoding 
the vitamin D receptor (Morrison et al., 1994). Vitamin D 
stimulates osteoclast and osteoblast differentiation i vitro 
and regulates bone mineralization and homeostasis in 
vivo, but how changes in receptor expression lead to the 
cellular changes resulting in osteoporosis remains un- 
clear. A potentially fruitful new approach to the problem 
is to establish appropriate transgenic mouse models to 
study the many paracrine growth and differentiation fac- 
tors that, based upon cell culture studies, have been impli- 
cated in bone remodeling (see below). The initial success 
of this approach can be seen with the demonstration that 
transgenic mice overexpressing interleukin-4 develop os- 
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teoporosis due to impaired osteoblastic function (Lewis et 
al., 1993). 
The Role of Collagens 
Collagens represent he major proteins in bone and carti- 
lage matrices and play an important role in determining 
the size, shape, and strength of these tissues (reviewed 
by van der Rest and Garrone, 1991). Collagens form a 
family of at least 25 members, several of which are ex- 
pressed at defined times and places during endochondral 
bone formation: collagen type II is the principal protein of 
cartilage, collagen type X is the major protein found in 
hypertrophic cartilage, and collagen type I is the most 
abundant protein in bone. All collagens contain globular 
domains at the amino and carboxyl termini and a triple- 
helical domain in between. Newly synthesized collagen 
monomers associate into trimeric microfibrils, which, once 
secreted, aggregate into larger structures. Based on their 
structure, the collagens can be subdivided into six distinct 
categories. Among these, the fibrillar collagens include 
types I, II, and Xl, the fibril-associated collagens include 
type IX, and the network collagens include type X collagen. 
The recent characterization of collagen mutations in mice 
and humans has provided insights into the function of dif- 
ferent collagens in cartilage and bone (reviewed by Tilstra 
and Byers, 1994). 
The best-characterized fibrillar collagen is the type I col- 
lagen, which consists of two (~1(I) and one ~2(I) polypep- 
tide chains. Mutations in the corresponding procollagen 
genes cause osteogenesis imperfecta, a heritable disor- 
der resulting in decreased bone mass and bone fragility 
(reviewed by Byers and Steiner, 1992; Willing et al., 1993). 
In addition, a wide range of clinical defects ranging from 
isolated osteoporosis to recurrent fractures and death in 
utero are also associated with collagen type I mutations. 
Several of the more than 100 molecular defects in procolla- 
gen type I genes characterized in humans have been re- 
constituted in transgenic mice with resulting bone defects. 
Analysis of human and mouse mutations have shown that 
null alleles give rise to mild phenotypes. Such mutations 
may result in altered mRNA levels or instability of the pro- 
tein, perhaps through its inability to polymerize with the 
wild-type monomers. More severe phenotypes result from 
dominant negative mutations that result in an aberrant 
protein still capable of multimerizing with wild-type colla- 
gen type I fibrils. The severity of the phenotype depends 
on the nature and location of the mutation and on its effects 
on protein structure. In general, the impact of point muta- 
tions on the phenotype decreases as the mutation shifts 
toward the amino-terminal portion of the molecule. The 
relationship between genotype and phenotype has been 
reviewed elsewhere (Kuivaniemi et al., 1991). 
Mutations in collagen type II, a homotrimer of (~1(11), 
have been correlated with a variety of chondrodysplasias 
(reviewed by Vikkula et al., 1994). This heterogeneous 
group of cartilage disorders may result in dwarfism, joint 
deformities, and other skeletal anomalies. As with colla- 
gen type I mutations, many different molecular defects 
have been reported, with dominant negative mutations 
resulting in the most severe defects in cartilage develop- 
ment and structure. The available transgenic mouse mod- 
els with defects in collagen type II s/mould help clarify how 
such cartilage mutations affect subsequent endochondral 
bone formation. Recently, a patient with impaired chondro- 
genesis and with a documented dominant negative muta- 
tion in the (~1(11) gene was found to express collagen type 
I in chondrocytes, suggesting a possible compensatory 
mechanism for aberrant collagen type II expression (Frei- 
singer et al., 1994). 
In this issue of Ceil, Li et al. (1995) and Vikkula et al. 
(1995) provide the first insights into the role of another 
fibrillar collagen, collagen type XI, in bone and cartilage 
formation. This minor component of cartilage collagen is 
thought to play a role in the regulation of collagen fibril 
diameter and the association of proteoglycans with the 
collagen fibrillar network. Li et al. (1995) report that a muta- 
tion in collagen type Xl lies at the basis of chondrodys- 
plasia in cho/cho mice. In these mice, the absence of 
al(Xl) collagen expression results in severe abnormalities 
in cartilage of the limbs, ribs, mandible, and trachea and 
death at birth. At the epiphyses, the columnar arrange- 
ment of chondrocytes is disordered and chondrocytic mat- 
uration is delayed. In addition, the bones are wider but 
only about half the normal overall length. The collagen 
fibrils are abnormally thick and the proteoglycans are 
readily extractable, which is consistent with the purported 
function of collagen type XI. Vikkula et al. (1995) correlate 
a dominant negative mutation in the human COL11A2 
gene encoding the ~2(Xl) chain with a form of Stickler 
syndrome, which is characterized by mild spondyloepiphy- 
seal dysplasia, osteoarthritis, and sensorineural hearing 
loss. They also mapped a more severe autosomal reces- 
sive human osteochondrodysplasia tothe COL 11A2 gene, 
and they speculate that this disease arises from a mutation 
resulting in a null allele. If this indeed proves to be the 
case, then it will be interesting to determine why such a 
mutation is lethal in the cho/cho mouse but not in human; 
as Vikkula et al. suggest, alternate collagen family mem- 
bers may be able to compensate for the null mutations in 
humans. 
Collagen type IX is a prototype of another subset of 
collagens, the fibril-associated collagens. This collagen 
localizes to the surface of collagen II fibrils and was 
thought to play a major role in development. However, 
transgenic overexpression of a dominant negative mutant 
of collagen IX (Nakata et al., 1993) and gene inactivation 
in mice (Fassler et al., 1994) result in surprisingly mild 
phenotypes, characterized by degenerative joint disease 
resembling hur:nan osteoarthritis and mild chondrodys- 
plasia. Thus, collagen IX may not play a major role in os- 
teogenesis and chondrogenesis or in other human osteo- 
chondrodysplasias. 
Finally, collagen X, a prototype of short chain collagens, 
is exclusively expressed in hypertrophic chondrocytes, 
where it forms distinct hexagonal arrays. Although its spe- 
cific role in hypertrophic cartilage is not known, it may 
serve as a substrate for mineralization or vascular inva- 
sion. Some insight into its function has been gained 
through analysis of transgenic mouse models and charac- 
terization of human mutations (reviewed by Jacenko et 
al., 1994). Mice with a mutant type X collagen transgene 
exhibit compression of the hypertrophic growth plate carti- 
lage and decreased bone formation in a pattern that re- 
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sembles spondylometaphyseal dysplasia and metaphy- 
seal chondrodysplasias in humans. Subsequent analysis 
has confirmed that such patients indeed bear collagen X 
mutations, which are all localized to the carboxy-terminal, 
non-triple helical domain of the protein. The lack of detect- 
able abnormalities in mice with an inactivated type X gene 
suggests that other collagens may compensate for its ab- 
sence and emphasize again that null alleles of collagens 
result in a less severe phenotype than overexpression of 
a dominant negative mutant. 
Mesenchymal Differentiation 
The study of bone and cartilage cell differentiation i  vitro 
provides an important counterpoint to the study of these 
cell populations in vivo. For example, experiments on cells 
derived from osteopetrotic mouse mutants will continue 
to add to the in vitro characterization ofosteoclast differen- 
tiation. In vitro approaches have also made valuable contri- 
butions to our understanding of the differentiation ofchon- 
drecytes and osteoblasts. By analogy with other cell types, 
chondrocyte and osteoblast differentiation involves at 
least two distinct processes. First, precursor cells commit 
to the cartilage or bone lineages. Since these two lineages 
probably arise from the same population of undifferenti- 
ated mesenchymal cells, these studies have mainly con- 
centrated on embryonic primary cultures and pluripotential 
mesenchymal cell lines. Second, consecutive maturation 
events lead to a fully differentiated phenotype, a process 
required in vivo for the constant replenishment of cartilage 
and bone cells from their respective committed precursor 
cell populations. Studies on the acquisition and modula- 
tion of the differentiated phenotype have mostly relied on 
cultures of committed precursor cells and tumor cell lines. 
Members of the TGFI3 superfamily of secreted growth 
and differentiation factors have received considerable at- 
tention as potent regulators of mesenchymal differentia- 
tion in vivo and in vitro. Several BMPs are thought o regu- 
late the early commitment of mesenchymal cells to the 
chondrogenic and osteogenic lineages, as suggested by 
their ability to induce ectopic cartilage and bone formation 
at nonskeletal sites such as muscle (Wozney et al., 1988; 
Wozney, 1992). Accordingly, these factors can stimulate 
osteoblastic differentiation of both uncommitted and com- 
mitted mesenchymal cells in vitro (Vukicevic et al., 1989; 
Yamaguchi et al., 1991; Wozney, 1992) and can induce 
cells other than osteoblasts to express osteoblastic mark- 
ers (Katagiri et al., 1994). TGFI3 itself may regulate the 
further differentiation ofcommitted precursor cells, as sug- 
gested by its ability to induce cartilage and bone formation 
when administered under the periosteum (Joyce et al., 
1990), but not when injected into nonskeletal sites (Cen- 
trella et al., 1994). TGFJ3 has also been shown to stimulate 
chondrocytic differentiation i  vitro, but whether it modu- 
lates osteoblastic differentiation is unclear owing to differ- 
ential responses in various cell systems (reviewed by Cen- 
trella et al., 1994). The biological effects of different 
TGFJ3-related factors together with their expression pat- 
terns during cartilage and bone development suggest that 
distinct TGFI3s and BMPs act sequentially to drive succes- 
sive stages of differentiation (Lyons et al., 1989; Rosen 
et al., 1994). Consistent with such a model, differentiating 
cells may alter their responsiveness to these factors by 
modulating receptor levels (Centrella et al., 1994) and the 
associated signal transduction mechanisms (Siddhanti 
and Quarles, 1994). 
In vitro work has also identified many other extracellular 
factors that can modulate mesenchymal differentiation, 
including steroid and peptide hormones, growth and differ- 
entiation factors, and collagens and other extracellular ma- 
trix proteins. A full understanding of the effects of these 
factors on mesenchymal differentiation, however, has 
been hampered by the limitations of in vitro cell culture. 
One difficulty has been the lack of specific phenotypic 
markers to follow successive differentiation events. Type 
II collagen secretion is considered a major early marker of 
chondrocyte differentiation, while the synthesis of alkaline 
phosphatase is an early marker of osteoblast differentia- 
tion. Mature osteoblasts also produce osteopontin, osteo- 
nectin, and osteocalcin, three extracellular matrix proteins 
deposited together with type I collagen into mineralized 
bone matrix (Rodan and Noda, 1991). Unfortunately, only 
a few differentiation markers have been identified, and sev- 
eral of these, such as alkaline phosphatase, osteopontin, 
and osteonectin, are not specific for osteogenic differen- 
tiation, while others, such as osteocalcin, are rarely ex- 
pressed in vitro. In addition, mesenchymal cell lines and 
primary cultures of differentiating chondrocytes and osteo- 
blasts display a variable phenotype and are often a mixture 
of cell types at different stages of differentiation. Finally, 
cells are typically cultured on plastic without a substrate 
of extracellular matrix. Such conditions may not allow com- 
plete differentiation since interaction with extracellular ma- 
trix proteins and a three-dimensional structure may be 
required for full differentiation. Accordingly, the develop- 
ment of appropriate three-dimensional invitro systems is 
an important area of investigation (Stein and Lian, 1993). 
In vitro culture systems have also proven valuable in eluci- 
dating the cell-type specificity of signal transduction and tran- 
scriptional regulation. In this respect, mesenchymal cell lines 
are useful for the evaluation of osteoblast- and chondro- 
cyte-specific transcription factors. Those belonging to the 
bH LH family are of particular interest because of their role 
in the commitment and differentiation of many cell types. 
For example, factors of the muscle-specific MyoD family 
are required for the differentiation of skeletal myoblasts 
and can induce several cell types to express a skeletal 
muscle phenotype (Olson and Klein, 1994). In the case of 
osteoblasts, no specific bHLH genes have as yet been 
identified, yet indirect evidence suggests their existence. 
First, the expression of Id, an antagonist of bHLH protein 
binding to the promoter, is down-regulated uring osteo- 
blast differentiation (Ogata and Noda, 1991; Kawaguchi 
et al., 1992), and overexpression of Id inhibits osteoblastic 
differentiation (Murray et al., 1992). Second, the promoter 
regions of several genes expressed in osteoblasts contain 
E boxes, which can act as DNA-binding domains for bHLH 
proteins (Siddhanti and Quarles, 1994). Finally, induction 
of osteoblastic differentiation isassociated with increased 
binding of nuclear extracts to E boxes (Kawaguchi et al., 
1992). Once specific transcription factors are identified, 
studies assessing the interaction between these transcrip- 
tional regulators and known secreted osteoinductive fac- 
tors will be of great importance in understanding the pat- 
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terning and regulation of mesenchymal  differentiation in 
vivo. 
In conclusion,  recent studies of mice and humans with 
var ious skeletal abnormal i t ies  have pointed to many genes 
important in bone and cart i lage development .  In vivo and 
in vitro approaches  have also led to an understanding of 
some of the molecular  mechan isms that control the activity 
and differentiation of bone and cart i lage cells. In the future, 
the convergence  of these var ious approaches  should pro- 
v ide greater insight into the morphogenes is  of this com- 
plex organ system. 
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